Drug Profile
VX 522
Alternative Names: mRNA-3692; VX-522; VXc-0522; VXc-522Latest Information Update: 16 Feb 2024
Price :
$50
*
At a glance
- Originator Moderna Therapeutics; Vertex Pharmaceuticals
- Developer Vertex Pharmaceuticals
- Class Antifibrotics; RNA
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Cystic fibrosis